|
|
|
|
|
|
|
|
|
Honeywell Would Like to Help Speed the Pandemic Response
|
|
|
The corona virus (COVID-19) pandemic is a humanitarian and healthcare crisis that highlights the criticality of having strong production strategies ready to answer the call of patients when they are in need. Life sciences manufacturers leading the race against time to overcome this global threat must be poised to utilize technology as a strategic weapon. Innovation, safety, and speed - the currencies by which success will be measured - are the driving forces behind their efforts.
Honeywell believes the solution to most efficiently ramp up production of potential clinical therapies is to develop full commercial scale manufacturing automation while still in clinical trials. Parallel path development of an engineered solution can start with minimum formulation details of the final therapy. A manufacturer can apply digital transformation to the manual steps during clinical trials to prepare electronic submittals for FDA review. Then, the data can be used to prepare for final automation design, which can be rapidly configured once a therapy is approved. A treatment or vaccine can go from approval to production in as little as 4 weeks depending on processing needs.
Learn more about how to serve the needs of patients at an expedited pace - at a time of exceptional need.
This white paper illustrates how to:
Seamlessly link with the most modern equipment from any vendor, Leverage virtual and cloud solutions, Combine innovations to enable fast-track automation, and Achieve operations that are scalable and flexible to demand fluctuations.
Learn more about how to serve the needs of patients at an expedited pace - at a time of exceptional need.
|
|
|
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Pharmaceutical Technology, an MJH Life Sciences™ brand. You are on the mailing list as %%emailaddress%%.
|
|
